Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSE-2101
- Development stage
- Phase 2
- Lead developer
- OSE Immunotherapeutics
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
OSE-2101 (Tedopi) is a therapeutic cancer vaccine composed of ten optimized neoepitopes derived from five tumor-associated antigens (TAAs): CEA, HER2/neu, p53, MAGE 2/3. It is designed to stimulate cytotoxic T lymphocyte responses against cancer cells expressing these antigens. The vaccine works by presenting these epitopes to the immune system, thereby activating killer T-cells that can recognize and destroy tumor cells. Developed primarily for use in HLA-A2-positive patients with advanced cancers such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), OSE-2101 has demonstrated improved survival outcomes in certain patient subgroups with secondary resistance to immunotherapy and has shown positive results as maintenance therapy in combination with chemotherapy for PDAC[3][5][6][7][8].
- Brand names
- Tedopi
- Other names
- multi-neo-epitope vaccine OSE-2101
02
Targets
MAGEA2 (Melanoma-associated antigen 2)MAGEA3 (Melanoma-associated antigen 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on OSE-2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSE-2101.